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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To compare the benefits and harms of different antiviral regimens in patients with HBV-related liver cirrhosis.
B A C K G R O U N D
Description of the condition
Chronic hepatitis B virus (HBV) infection is a serious health prob-
lem because of its worldwide distribution and its potential adverse
sequelae, including cirrhosis, hepatocellular carcinoma, and death
(Lavanchy 2004). It is estimated that each year, worldwide, more
than 200,000 people, chronic carriers of HBV, die of liver cirrho-
sis, and more than 300,000 people, chronic carriers of HBV, die
of hepatocellular carcinoma (Perz 2006). Since HBV replication,
defined as the presence of hepatitis B e antigen (HBeAg) or HBV
deoxyribonucleic acid (DNA) more than 2000 international units
(IU)/mL in the blood, or both, may persist after the development
of cirrhosis, liver disease may continue to progress, and hepatic
decompensation or hepatocellular carcinoma may occur (Chen
2007). Hepatic decompensation usually presents with at least one
episode of ascites, jaundice, hepatic encephalopathy, or variceal
bleeding (De Jongh 1992).
An estimated 15% to 40% of untreated patients with chronic
HBV infection may develop cirrhosis, liver failure, hepatocellu-
lar carcinoma, or a combination of these (Lavanchy 2004). The
aim of anti-viral therapy in these patients is to prevent the devel-
opment of cirrhosis and its associated complications, in an effort
to improve patient survival and quality of life (Belongia 2008).
However, patients with decompensated HBV cirrhosis at initial
presentation have a poor short-term prognosis with an estimated
five-year survival of only 14% (De Jongh 1992). Although liver
transplantation is an effective treatment option for decompensated
HBV cirrhosis, the ongoing shortage of donor organs and limited
availability of this resource worldwide precludes the majority of
HBV patients in endemic areas from undergoing transplantation
(Liaw 2008).
Seven drugs are currently approved for themanagement of chronic
HBV infection: standard interferon, lamivudine, adefovir, ente-
cavir, pegylated interferon-alpha (peginterferon-alpha), telbivu-
dine, and tenofovir (Lok 2009). Interferons enhance host im-
munity against HBV-infected hepatocytes but have a number of
dose-dependent adverse effects including neuropsychiatric toxic-
ity and myelotoxicity, which preclude their safe use in patients
with advanced HBV (Lok 2009). Interferon was not only poorly
tolerated in patients with decompensated HBV cirrhosis but also
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associated with disease flares and worsening liver disease status
(Perrillo 1995). In contrast, oral anti-viral agents have a generally
favourable adverse effect profile and are well tolerated in patients
with compensated as well as decompensatedHBV (Liaw 2004). In
addition, these agents can directly and rapidly inhibit HBV repli-
cation and lead to improvement in hepatic necro-inflammation,
serum alanine aminotransferase levels, and global liver function
even in patients with advanced disease (Liaw 2004). All of these
antivirals are competitive inhibitors of theHBV DNA polymerase
via competition with the incorporation of the natural endogenous
intracellular nucleotides in nascent HBV DNA and cause DNA
chain termination. Furthermore, all of these nucleoside analogues
have activities conferring biochemical, virological, and serologi-
cal improvement in patients with chronic hepatitis B (Lok 2009;
EASL 2012; Liaw 2012). Nucleoside analogues can also retard the
progression of fibrosis and reverse fibrosis and cirrhosis (Dienstag
2003; Hadziyannis 2006; Chang 2010). Long-term therapy may
also prevent hepatic decompensation in patients with advanced fi-
brosis and cirrhosis (Liaw 2004). The generally favourable adverse
effect profiles of lamivudine, adefovir, entecavir, telbivudine, and
tenofovir, coupled with the low rates of anti-viral drug resistance
with newer agents such as entecavir, which had the lowest rate of
drug resistance in treatment-naive patients with HBeAg-positive
chronic hepatitis B, make them attractive for use beyond one year.
However, infrequent but serious adverse events such as myopa-
thy, neuropathy, and pancreatitis as well as reversible renal im-
pairment have been reported during post-marketing surveillance
(Keeffe 2006; Lok 2007).
The Child-Turcotte-Pugh (CTP) score and model for end-stage
liver disease (MELD) score are the two liver-specific scoring sys-
tems that have been used to assess disease severity in patients
with cirrhosis. The CTP score was originally developed to predict
post-operative mortality in bleeding patients with alcoholic liver
cirrhosis undergoing portal-systemic shunt surgery (Pugh 1973).
Although it predicts one-year survival and post-surgical risks of
complications, it does not predict short-termmortality (Schuppan
2008). The MELD score was initially developed to predict short-
term mortality in patients undergoing transjugular intrahepatic
portosystemic shunting (Malinchoc 2000). It was later used to
predict three-month mortality in patients with cirrhosis, irrespec-
tive of cause, and has been adopted to prioritise organ allocation
for liver transplantation in the United States since 2002 (Kamath
2001; Wiesner 2003). A major feature of the MELD scoring sys-
tem is the inclusion of renal function in themodel. Renal dysfunc-
tion commonly occurs during the course of disease progression
in cirrhosis and has been shown to have a detrimental prognostic
impact on survival (Fernandez 2001).
Description of the intervention
Oral antiviral agents for treatment of HBV, such as lamivudine,
adefovir, entecavir, telbivudine, and tenofovir, are chemicallymod-
ified analogues of naturally occurring nucleosides or nucleotides
that pharmacologically inhibit the polymerase activity of HBV,
leading to reduced viral replication and decreases in serum HBV
DNA levels.
How the intervention might work
Antiviral agents could improve a patient’s quality of life and de-
crease the progression to liver cirrhosis and chances of developing
hepatocellular carcinoma as well as the risk of death.
Why it is important to do this review
Although antiviral agents seem to be beneficial for patients with
HBV-related cirrhosis, these drugs have a warning because of their
potential for inhibition of human DNA polymerase gamma in-
volved inmitochondrial DNA replication. A reduction in intracel-
lular mitochondrial DNA levels can lead to varying clinical man-
ifestations of mitochondrial toxicity in long-term treatment. So,
there is no clear safety profile of the nucleoside analogues when
given alone or in combination for prolonged periods of time. This
review aims to provide evidence of the beneficial and harmful ef-
fects of treatment with antiviral agents in patients with HBV-re-
lated liver cirrhosis.
There are currently two Cochrane systematic review protocols that
concentrate on chronic hepatitis B. Whitfield 2010 is evaluating
the beneficial and harmful effects of levamisole for patients with
chronic hepatitis B while Zhao 2010 is evaluating the effects of
telbivudine for chronic hepatitis B.
To date, no systematic review has been conducted on the benefits
and harms of antiviral agents for liver cirrhosis related to hepatitis
B and their effect on progression of cirrhosis and developing of
hepatocellular carcinoma.
O B J E C T I V E S
To compare the benefits and harms of different antiviral regimens
in patients with HBV-related liver cirrhosis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will consider all randomised clinical trials that assess antiviral
intervention in patients with HBV-related cirrhosis. We will use
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non-randomised clinical studies retrieved with the searches for
randomised trials for extraction on data on harm only.
Types of participants
Adults at the age of 18 years or above, of either sex, who have been
diagnosed with HBV-related cirrhosis. Diagnosis of HBV should
have been based on the presence of detectable HBV DNA by a
DNA hybridisation method or polymerase chain reaction, and the
cirrhosis should be related to the HBV.
Criteria for the diagnosis of cirrhosis should be patients with def-
inite diagnosis of cirrhosis based on liver biopsy or laboratory, ra-
diographic, or Fibro scan findings compatible with the diagnosis
of cirrhosis.
The randomised clinical trials should have included participants
with compensated or decompensated HBV-related liver cirrhosis.
We will exclude chronic HBV patients who do not have developed
cirrhosis, patients with liver cirrhosis unrelated to HBV, patients
with liver cirrhosis with combined HBV andHCV, and those with
hepatocellular carcinoma.
Types of interventions
The experimental intervention will be antiviral drugs against HBV
asmonotherapy (lamivudine, adefovir dipivoxil, entecavir, telbivu-
dine, or tenofovir disoproxil fumarate) at any dose and minimum
duration of six months, or a combination of these antiviral agents.
We will compare one intervention versus placebo, no treatment,
or another antiviral treatment.
Types of outcome measures
Primary outcomes
1. All-cause mortality.
2. Hepatic-related mortality.
3. Non-fatal serious adverse events: serious adverse events are
defined according to the International Conference on
Harmonisation (ICH) Guideline for Good Clinical Practice
(ICH-GCP 1997), as any event that is life threatening, requires
inpatient hospitalisation or prolongation of existing
hospitalisation, results in persistent or significant disability, and
any important medical event, which may have jeopardised the
patient or requires intervention to prevent it.
4. Quality of life (using standardised objective scales: i.e.,
Health Day Measures questionnaire, Short-form Health Survey,
Manchester Short Assessment of Quality of Life, EQ-5D, World
Health Organization (WHO)-Quality of life BREF, etc.)
Secondary outcomes
1. Number of patients without improvement of cirrhosis
progression by MELD score according to CTP score.
2. Number of patients who developed hepatocellular
carcinoma.
3. Number of patients with non-serious adverse events.
Search methods for identification of studies
Electronic searches
We will search The Cochrane Hepato-Biliary Group Controlled
Trials Register (Gluud 2013), the Cochrane Central Register of
Controlled Trials (CENTRAL), MEDLINE, EMBASE, and Sci-
ence Citation Index Expanded (including Conference Proceed-
ings Citation Index-Science) (Royle 2003). The search strategies
for each database with the expected time spans of the searches are
listed in Appendix 1. If needed, we will improve the searches at
the review stage.
Searching other resources
Abstracts from the European Association for the Study of Liver
disease (EASL) published in Journal of Hepatology and from the
American Association of Study of Liver Disease (AASLD) pub-
lished inHepatology will be obtained through The Cochrane Hep-
ato-Biliary Group Controlled Trials Register.
Data collection and analysis
Selection of studies
We will assess the titles and abstracts of records retrieved from
the search by using at least two review authors in order to re-
duce the possibility that relevant reports are discarded. We will
evaluate titles and abstracts to remove obviously irrelevant reports
and will merge search results in order to remove duplicate records
of the same report. Then, we will retrieve full text of the poten-
tially relevant reports. We will also examine full-text reports for
compliance of studies with eligibility criteria. If it is necessary, we
will correspond with investigators, where appropriate, to clarify
study eligibility and request further information, such as missing
results. The review authors will independently select studies to be
included in the review. We will include a list of excluded studies
with giving the primary reasons for the exclusions. Wherever dis-
agreement occurs, we will generally resolve it by discussion or by
asking arbitration by another person.
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Data extraction and management
We will include studies with some characteristics such as:
• Details of participants: age (mean (standard deviation)), sex
(%), number of patients randomised; inclusion and exclusion
criteria, ethnicity, sociodemographic details (e.g., education
level) and the presence of co-morbid conditions.
• Details of trial: timing of the studies, the settings of studies,
and funding of the trials; trials design; length of follow-up; use of
intention-to-treat analysis; and publication status.
• Details of Interventions: routes of delivery, doses, length of
treatment, of additional intervention(s), and a different regimen
of treatment, placebo or no treatment in the control group.
• Criteria for the diagnosis of cirrhosis will be patients with
definite diagnosis with liver biopsy or laboratory, radiographic,
or Fibro scan findings compatible with the diagnosis of cirrhosis.
• Details of outcome: definition, unit of measurement,
number of mortality, non-fatal serious adverse events, serious
adverse events, life-threatening events, disabilities, and any
important medical events, and quality of life.
We will design the data collection forms and will record the name
(or identification number) of the person who is completing the
forms. We will also include assessment (or verification) of eligi-
bility of the study for the review. At least two review authors will
independently extract data from every report to minimise errors
and reduce potential biases being introduced by review authors.
We will pilot test all forms using a representative sample of the
studies to be reviewed. Where disagreement occurs, it will be re-
solved by discussion among the review authors (at first step) or by
arbitration by another person, or by contacting the study authors.
Assessment of risk of bias in included studies
We will follow the instructions given in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011), and The
Cochrane Hepato-Biliary Group Module (Gluud 2013). We will
define methodological quality as the confidence that the design
and the report of the randomised clinical trial would restrict bias
in the comparison of the intervention (Moher 1998). According
to empirical evidence (Schulz 1995;Moher 1998; Kjaergard 2001;
Wood 2008; Higgins 2011; Lundh 2012; Savovi 2012; Savovi
2012a), the methodological quality of the trials, hence risk of bias,
will be assessed as follows:
Allocation sequence generation
• Low risk of bias: sequence generation was achieved using
computer random number generation or a random number
table. Drawing lots, tossing a coin, shuffling cards, and throwing
dice were adequate if performed by an independent person not
otherwise involved in the trial.
• Uncertain risk of bias: the method of sequence generation
was not specified.
• High risk of bias: the sequence generation method was not
random.
Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. Allocation
was controlled by a central and independent randomisation unit.
The allocation sequence was unknown to the investigators (e.g. if
the allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
• Uncertain risk of bias: the method used to conceal the
allocation was not described so that intervention allocations may
have been foreseen in advance of, or during, enrolment.
• High risk of bias: the allocation sequence was likely to be
known to the investigators who assigned the participants.
Blinding of participants, personnel, and outcome assessors
• Low risk of bias: blinding was performed adequately, or the
assessment of outcomes was not likely to be influenced by lack of
blinding.
• Uncertain risk of bias: there was insufficient information to
assess whether blinding was likely to induce bias on the results.
• High risk of bias: no blinding or incomplete blinding, and
the assessment of outcomes were likely to be influenced by lack
of blinding.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. Sufficient
methods, such as multiple imputation, were employed to handle
missing data.
• Uncertain risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data were likely to induce bias on the
results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk of bias: all outcomes were pre-defined and
reported, or all clinically relevant and reasonably expected
outcomes were reported.
• Uncertain risk of bias: it is unclear whether all pre-defined
and clinically relevant and reasonably expected outcomes were
reported.
• High risk of bias: one or more clinically relevant and
reasonably expected outcomes were not reported, and data on
these outcomes were likely to have been recorded.
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For a trial to be assessed with low risk of bias in the selective out-
come reporting domain, the trial should have been registered on
the www.clinicaltrials.gov website or a similar register, or there
should be a protocol (e.g., published in a paper journal). In the
case when the trial was run and published in the years when trial
registration was not required, we will carefully scrutinise all pub-
lications reporting on the trial to identify the trial objectives and
outcomes. If usable data on all outcomes specified in the trial ob-
jectives were provided in the publications results section, then the
trial can be considered a low risk of bias trial in the ’Selective out-
come reporting’ domain.
For-profit bias
• Low risk of bias: the trial appears to be free of industry
sponsorship or other type of for-profit support that may
manipulate the trial design, conductance, or results of the trial.
• Uncertain risk of bias: the trial may or may not be free of
for-profit bias as no information on clinical trial support or
sponsorship was provided.
• High risk of bias: the trial was sponsored by the industry or
has received other type of for-profit support.
Other bias
• Low risk of bias: the trial appears to be free of other
components (e.g. academic bias) that could put it at risk of bias.
• Uncertain risk of bias: the trial may or may not be free of
other components that could put it at risk of bias.
• High risk of bias: there are other factors in the trial that
could put it at risk of bias (e.g. authors have conducted trials on
the same topic, etc.).
We will consider trials assessed as having ’low risk of bias’ in all of
the above specified individual domains as trials with ’low risk of
bias’. We will consider trials assessed as having ’uncertain risk of
bias’ or ’high risk of bias’ in one or more of the specified individual
domains as trials with ’high risk of bias’ .
If disagreements among review authors’ evaluation occur, we will
resolve them by discussion.
Measures of treatment effect
We will use the software package Review Manager 5 provided by
The Cochrane Collaboration (RevMan 2012).
Dichotomous data
The effect measures of choice are risk ratio or risk difference or
both, and number needed to treat for an additional beneficial
outcome (NNTB) with 95% confidence interval (CI), using both
fixed-effect and random-effects meta-analysis models. Risk ratio
calculations do not include trials in which no events occur in the
groups, whereas risk difference calculations do. This is why we
plan to report the results of both effect measures if the conclusions
reached at differ due to the trials with zero events in the groups.
P values of all trialswill be calculated based on theMantel-Haenszel
method. The Review Manager 5 software automatically adds 0.5
to each cell of the 2 x 2 table for any study with zero events (e.g.
no events in one group) (RevMan 2012), so the problems with
computation of estimates and standard errors will be eliminated.
Mantel-Haenszel methods have better statistical properties when
there are few events.
Continuous data
We will present the results as mean differences (MD) with 95%
CI using the fixed-effect and random-effects models. P values of
all trials will be calculated based on the generic inverse variance.
When pooling data across trials, we will estimate the MD if the
outcomes are measured in the same way between trials. We will
use the standardised mean difference (SMD) to combine trials
that measure the same outcome but use different methods. If it is
only one trial that provides data on an outcome specified in the
protocol, meta-analyses will not be possible, and we will report
and discuss this in the review.
Time to event data
We will analyse time-to-event data as dichotomous data using a
fixed time point, so the proportion of patients who have incurred
the event before the time point will be known for both groups.
We will then construct a 2 x 2 table, and we will express treatment
effects as risk ratios, odds ratios, or risk differences.
When overall results are statistically significant by both fixed- and
random-effects models, we will calculate the relative risk reduction
(RRR), NNTB, and the number needed to treat for an additional
harmful outcome (NNTH).
Unit of analysis issues
The unit of analysis will be the patients recruited into the trial.
We will include simple parallel randomised clinical trials, as well
as cluster randomised trials and cross-over trials, in the meta-anal-
yses. We will identify any cluster-randomised trials that will be
included for the review, but we will not combine these with indi-
vidually randomised trials in the same meta-analysis (i.e. they will
be analysed separately). We will meta-analyse effect estimates and
their standard errors from correct analyses of cluster-randomised
trials using the generic inverse-variance method in Review Man-
ager 5 (RevMan 2012). Care will be taken to avoid ’unit of anal-
ysis’ errors when analysing these types of trials (Higgins 2011).
The cross-over trial is not a suitable method for the condition
and intervention in our question because the intervention (i.e.
antiviral agents) could have a lasting effect that compromises entry
to subsequent periods of the trial. In the presence of carry-over,
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we will include only data from the first period of a cross-over trial
in the meta-analysis. The first period of a cross-over trial is in fact
a parallel group comparison. So, in case of cross-over studies, we
will follow the guidelines in the Cochrane Handbook for Systematic
Reviews of Interventions on how to deal with data from cross-over
studies (Higgins 2011). We will also perform sensitivity analysis
with inclusion of only simple parallel randomised clinical trials in
the meta-analysis.
Dealing with missing data
We will contact study authors for data that were measured but not
reported. We will perform all analyses according to the intention-
to-treat method, including all participants irrespective of compli-
ance or follow-up. Regarding the four primary outcomes, we will
include patients with incomplete or missing data in the sensitivity
analyses by imputing them according to the following two extreme
scenarios (Hollis 1999; Gluud 2013):
• Extreme case analysis favouring the experimental
intervention (’best-worse’ case scenario): none of the drop-outs/
participants lost from the experimental arm, but all of the drop-
outs/participants lost from the control group experienced the
outcome, including all randomised participants in the
denominator.
• Extreme case analysis favouring the control (’worst-best’
case scenario): all drop-outs/participants lost from the
experimental arm, but none from the control arm experienced
the outcome, including all randomised participants in the
denominator.
Assessment of heterogeneity
We will formally test for statistical heterogeneity using the Chi2
test for statistical homogeneity with a P value < 0.1 set as the cut-
off. The impact of any statistical heterogeneity will be quantified
using the I2 statistic (Higgins 2011).
We will interpret the I2 value as:
• 0% to 40%: might not be important.
• 30% to 60%: may represent moderate heterogeneity.
• 50% to 90%: may represent substantial heterogeneity.
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
We will assess publication bias by looking for funnel plot asym-
metry if there are at least 10 included trials (Egger 1997).
Data synthesis
We will perform the meta-analyses using the software package Re-
view Manager 5 (RevMan 2012), and following the recommen-
dations of The Cochrane Collaboration (Higgins 2011), and The
Cochrane Hepato-Biliary Group Module (Gluud 2013). We will
use both random-effects model (DerSimonian 1986) and fixed-ef-
fect model (DeMets 1987) meta-analyses. We will use the generic
inverse variance method in Review Manager 5 (Higgins 2011;
RevMan 2012). In case of discrepancy in the results of twomodels,
we will present the results using both methods. If there is no sta-
tistically significant difference in the results, then we will present
the results using the fixed-effect model.
If the data are not available for meta-analyses or if meta-analyses
are considered an inappropriate tool for the included trials, we will
attempt to present the data of such outcomes in a descriptive way.
Trial sequential analysis
Trial sequential analysis (TSA) is a tool for quantifying the sta-
tistical reliability of the data in a cumulative meta-analysis (CTU
2011;Thorlund 2011), controlling for randomerrors due to sparse
data and repetitive testing on accumulating data (Brok 2008;
Wetterslev 2008; Brok 2009; Thorlund 2009, Wetterslev 2009;
Thorlund 2010; Thorlund 2011a). TSA is a methodology that
combines a required information size calculation (cumulated sam-
ple sizes of trials to prove or disprove a certain intervention effect)
with the threshold of statistical significance. We will base our cal-
culations on the diversity-adjusted required information size for
dichotomous outcomes on the proportion of patients with the
outcome in the conventional group, a RRR of 20%, an alpha (type
I error) of 5%, a beta (type II error) of 20% (power 80%), and the
diversity of the meta-analysis (Wetterslev 2009). We may perform
sensitivity analyses choosing other variables.
Subgroup analysis and investigation of heterogeneity
We plan to perform subgroup analyses on the following items:
• Trials with low risk of bias compared to trials with high risk
of bias.
• Trials with co-interventions compared to the trials without
co-interventions.
• Patients co-infected with HIV compared to patients
without co-infection.
• Cirrhosis progression at entry into the trial; comparing the
interventions effects in trials with compensated cirrhosis to the
ones with decompensated cirrhosis.
• Trials without losses to follow-up compared to trials with
losses to follow-up.
• Trials published as full paper articles compared to trials
published as abstracts only.
Sensitivity analysis
We will exclude from the meta-analyses the trials in which alloca-
tion concealment was not described or was likely to be known to
the investigators who assigned the participants.
Wewill conduct ’best-worst’ and ’worst-best’ case scenario analyses
as already described in Dealing with missing data.
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Summary of findings’ tables
Wewill summarise the evidence on all binary outcomes in a ’Sum-
mary of findings’ table, using GRADEpro (ims.cochrane.org/
revman/other-resources/gradepro).
A C K N OW L E D G E M E N T S
Peer reviewers: Angelo Andriulli, Italy; Alessio Aghemo, Italy.
Contact editor: Davor Štimac, Croatia.
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A P P E N D I C E S
Appendix 1. Search strategies
Database Time span Search strategy
TheCochraneHepato-BiliaryGroupCon-
trolled Trials Register
Date will be given at review stage. ((antiviral and (drug* or agent*)) or lamivudine
or adefovir dipivoxil or entecavir* or telbivudin*
or tenofovir*) AND (hepatitis B or hep B or hbv)
AND (cirrho* or fibro*)
Cochrane Central Register of Controlled
Trials (CENTRAL)
Latest issue. #1MeSH descriptor: [Antiviral Agents] explode all
trees
#2 (antiviral and (drug* or agent*)) or lamivudine
9Antiviral agents for hepatitis B virus-related cirrhosis (Protocol)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
or adefovir dipivoxil or entecavir* or telbivudin* or
tenofovir*
#3 #1 or #2
#4MeSH descriptor: [Hepatitis B] explode all trees
#5 hepatitis B or hep B or hbv
#6 #4 or #5
#7 MeSH descriptor: [Liver Cirrhosis] explode all
trees
#8 cirrho* or fibro*
#9 #7 or #8
#10 #3 and #6 and #9
MEDLINE (Ovid SP) 1946 to the date of search. 1. exp Antiviral Agents/
2. ((antiviral and (drug* or agent*)) or lamivu-
dine or adefovir dipivoxil or entecavir* or tel-
bivudin* or tenofovir*).mp. [mp=title, abstract,
original title, name of substance word, subject
heading word, keyword heading word, protocol
supplementary concept, rare disease supplementary
concept, unique identifier]
3. 1 or 2
4. exp Hepatitis B/
5. (hepatitis B or hep B or hbv).mp. [mp=title, ab-
stract, original title, name of substance word, sub-
ject heading word, keyword heading word, pro-
tocol supplementary concept, rare disease supple-
mentary concept, unique identifier]
6. 4 or 5
7. exp Liver Cirrhosis/
8. (cirrho* or fibro*).mp. [mp=title, abstract, orig-
inal title, name of substance word, subject head-
ing word, keyword heading word, protocol supple-
mentary concept, rare disease supplementary con-
cept, unique identifier]
9. 7 or 8
10. 3 and 6 and 9
11. (random* or blind* or placebo* or meta-
analys*).mp. [mp=title, abstract, original title,
name of substance word, subject heading word,
keyword heading word, protocol supplemen-
tary concept, rare disease supplementary concept,
unique identifier]
12. 10 and 11
EMBASE (Ovid SP) 1974 to the date of search. 1. exp antivirus agent/
2. ((antiviral and (drug* or agent*)) or lamivudine
or adefovir dipivoxil or entecavir* or telbivudin* or
tenofovir*).mp. [mp=title, abstract, subject head-
ings, heading word, drug trade name, original ti-
tle, devicemanufacturer, drugmanufacturer, device
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(Continued)
trade name, keyword]
3. 1 or 2
4. exp hepatitis B/
5. (hepatitis B or hep B or hbv).mp. [mp=title, ab-
stract, subject headings, heading word, drug trade
name, original title, device manufacturer, drug
manufacturer, device trade name, keyword]
6. 4 or 5
7. exp liver cirrhosis/
8. (cirrho* or fibro*).mp. [mp=title, abstract, sub-
ject headings, headingword, drug trade name, orig-
inal title, device manufacturer, drug manufacturer,
device trade name, keyword]
9. 7 or 8
10. 3 and 6 and 9
11. (random* or blind* or placebo* or meta-
analys*).mp. [mp=title, abstract, subject headings,
heading word, drug trade name, original title, de-
vice manufacturer, drugmanufacturer, device trade
name, keyword]
12. 10 and 11
Science Citation Index Expanded 1900 to the date of search. #5 #4 AND #3 AND #2 AND #1
#4 TS=(random* or blind* or placebo* or meta-
analys*)
#3 TS=(cirrho* or fibro*)
#2 TS=(hepatitis B or hep B or hbv)
#1 TS=((antiviral and (drug* or agent*)) or lamivu-
dine or adefovir dipivoxil or entecavir* or tel-
bivudin* or tenofovir*)
WH A T ’ S N E W
Date Event Description
22 May 2014 Amended The letter ’h’ was omitted in the name of the third author, Khatereh Isazadehfar
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